Goodwin Biotechnology, Inc. (GBI) has completed the expansion of its cGMP manufacturing space, doubling its capacity. The expansion includes the addition of a 200L and 500L stirred tank bioreactor train to its hollow fiber and perfusion capabilities, and is in response to the growing industry needs for biological manufacturing.      Stephanie Finnegan, GBI’s chief executive officer, said, “This is the culmination of a dream we envisaged a decade ago.  This was finally made possible by ...